EGFR and neoplasm: Since 50–60% of tumor progressions on 1L EGFR TKI are caused by the occurrence of the T790M resistance mutation [8,9,10], the number of patients with a potential benefit from osimertinib as 2L therapy when T790M mutation is present would have been higher if all progressing patients from our cohort would have been tested.